Septerna (NASDAQ:SEPN) Sets New 52-Week High – Should You Buy?

Septerna, Inc. (NASDAQ:SEPN) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $28.99 and last traded at $27.09, with a volume of 365987 shares changing hands. The stock had previously closed at $24.28.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. JPMorgan Chase & Co. started coverage on Septerna in a research note on Tuesday, November 19th. They set an “overweight” rating and a $38.00 price objective for the company. Wells Fargo & Company began coverage on Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $43.00 price target for the company. Cantor Fitzgerald initiated coverage on Septerna in a research report on Tuesday, November 19th. They issued an “overweight” rating and a $50.00 price objective on the stock. Finally, TD Cowen began coverage on shares of Septerna in a report on Tuesday, November 19th. They set a “buy” rating for the company.

Septerna Price Performance

The business’s 50 day simple moving average is $23.72.

Insiders Place Their Bets

In related news, major shareholder Rock Ventures V. L.P. Third acquired 370,500 shares of the firm’s stock in a transaction dated Monday, October 28th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $6,669,000.00. Following the acquisition, the insider now owns 6,215,591 shares in the company, valued at $111,880,638. The trade was a 6.34 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.